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H-FABPAbstract Background: Children with congenital heart disease (CHD) who have relevant systemic-
to-pulmonary shunts will develop pulmonary hypertension (PH) if untreated. With advances in
medical research, new biomarkers representing different physiological processes continue to emerge,
providing an ever clearer risk profile for patients with PH.
Aim: To evaluate the role of serum galectin-3 and heart fatty acid binding protein (H-FABP) as
early predictive biomarkers of PH in children with ventricular septal defect (VSD).
Method: The study included 50 children with VSD; 24 of them had PH and 25 age and sex matched
healthy children serve as a control group. Serum levels of galectin-3, H-FABP and echocardiogra-
phy evaluation were done for all cases and control subjects. We investigated the correlation between
these markers and pulmonary pressure in children with VSD.
Results: Serum levels of galectin-3 and H-FABP were significantly higher in patients with PH.
There was a significant positive correlation between both markers and pulmonary pressure.
Galectin-3 and H-FABP have 76%, 60% sensitivity and 80%, 96% specificity respectively for
prediction of PH in children with VSD.
Conclusion: Galectin-3 and H-FABP are promising cardiac biomarker for prediction and risk
stratification of PH in children with VSD.
 2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Ventricular septal defect is one of the most common congenital
heart diseases occurring in 50% of all children with congenitalheart disease. The size of the VSD, the pressure in right and
left ventricles, and pulmonary vascular resistance are factors
that determine the hemodynamic changes in children with
VSD.1
Left to right shunt through septal defect increases both
blood pressure and flow through the pulmonary circulation,
thus, in turn, induces irreversible changes of the medium-
sized and small pulmonary arteries results in pulmonary
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resistance (PVR) and reversal of shunt.2 The minimum value
of PVR increase remains controversial, especially in pediatric
age group.3 Prevention of this sequence of events is an impor-
tant target in the management of septal defects, and may, in
particular, motivate surgical intervention for closure of the
defect. However, the clinical course of patients with septal
defects is variable. In particular, it is not known how
frequently PH develops and at which levels symptoms and
irreversible changes will occur before closure of the defect.4
Pulmonary hypertension is a multifactorial and complex
vascular disorder. Clinically, children with PH show various
symptoms including shortness of breath, exercise intolerance,
fatigue, respiratory symptoms and chest pain. Most of these
symptoms are non-specific, and dependent upon age.5 Without
therapy, high PVR causes progressive right ventricular failure,
low cardiac output, and high mortality. Current diagnostic
methods include echocardiography, exercise testing and right
heart catheterization.6
There is an emerging need for non-invasive and objective
biomarkers to guide the diagnosis, treatment, and prognosis
of PH in children. Currently, several biomarkers arising from
sources related to ongoing processes of inflammation,
coagulation, and ventricular strain have been identified in
the pathophysiology of PH. However the multifactorial patho-
physiology, variable clinical presentation, and association with
other diseases make this a formidable challenge especially in
pediatric age group.7
Galectin-3 is a soluble b-galactoside-binding lectin secreted
by immune cells that regulate fibrogenesis, inflammation, cell
proliferation, and tissue repair. Galectin-3 is involved in
fibrosis in various organs, including the lung, liver, kidney,
and heart through the promotion of macrophage migration,
fibroblast proliferation and collagen synthesis.8
Heart type fatty acid-binding protein is a tissue specific
cytoplasmic protein of small molecular weight (12–15 KD)
that binds to long chain fatty acids and plays an important role
in the intracellular utilization of fatty acids.9 H-FABP is a
sensitive marker for detecting latent ongoing myocardial
damage and is a useful marker for detecting subjects at high
risk for adverse cardiac events.10 H-FABP can provide a
dynamic view of the remodeling process and give information
on the metabolic activity of cardiac muscles.11
In spite of the demonstrated role of galectin-3 and H-FABP
for detection of cardiac impairment in several categories of
patients with heart diseases, they are not widely studied for
evaluation of pulmonary hypertension.
On the basis of these previous observations, we conducted
the present study to determine whether galectin-3 and
H-FABP, alone or in combination with clinical or echocardio-
graphic findings, could reliably predict PH in children with
VSD.Patients and methods
This study is a cross sectional comparative study. It included
all children with VSD confirmed by echocardiography who
were referred to pediatric departments of Al-Azhar university
hospitals (Al-Zahraa University Hospital, Al-Hussein Univer-
sity Hospital and Sayed Galal University Hospital), Cairo,
Egypt during the period from July 2014 to March 2015. Theywere selected consecutively from both inpatients and outpa-
tients who fulfill our inclusion criteria. Serum levels of
galectin-3, H-FABP and echocardiography evaluation were
done for all cases and control subjects. We investigated the
correlation between these markers and pulmonary pressure
in children with VSD. Informed consent was obtained from
the participating parents in adherence to the guidelines of
the ethics committee of Al-Azhar University, Cairo, Egypt.
Inclusion criteria include children with echocardiography
confirmed VSD either with or without pulmonary hyperten-
sion, their age ranged between 6 months and 4 years.
Children with cyanotic heart disease, other structural heart
disease than VSD, cardiomyopathy, heart failure, acute illness,
non-cardiac systemic chronic diseases or those who underwent
previous surgical correction were excluded from the study.
Based on our inclusion and exclusion criteria; the current
study included 50 children with VSD; 24 of them had
pulmonary hypertension. In addition, 25 healthy children serve
as a control group. The control group was selected from age
and sex matched healthy siblings of diseased children who
had no structural heart disease confirmed by full history,
examination, echocardiography and fulfill the same exclusion
criteria for diseased group.
Clinical history and examination
All the studied children were subjected to a full history and
through clinical examination. Clinical history includes the
demographic data, presenting symptoms, any previous sur-
gery, and current medications. Full data were recorded regard-
ing manifestation of pulmonary congestion, low cardiac
output symptoms, acute or chronic heart failure and failure
to thrive. The findings of systemic and cardiac examinations
were recorded in details. Nutritional assessment was done
through dietetic history and anthropometric measurement
(weight and length for age, weight/height ratio, head circum-
ference, mid-arm circumference), presence of pallor and signs
of vitamins deficiency.
Echocardiography
Echocardiography was performed for all subjects in both
supine and left lateral position using Philips HD7.XE system.
All cases were examined using multiple transducers ranging
from 3.5 to 7 MHZ. with simultaneous electrocardiographic
recording to allow timing of flow. Uncooperative children were
given chloral hydrate according to body weight (50–5 mg/kg).
M-mode and 2D echocardiography was used to measure the
diameter of cardiac champers. PH is defined as a mean
pulmonary artery pressure equal to or greater than 25 mmHg.12
Laboratory investigations
Measurement of galectin-3 and H-FABP level
Samplings (blood samples). 3 ml of venous blood samples were
drawn under complete aseptic condition (alcohol swab 70%) in
BD vacutainers (plain gel separator vacutainer). The sample in
plain gel separator vacutainers was placed in water bath at
37 C for 20 min then centrifuged at 3000 rpm for 10 min.
Serum was aspirated in 2 Eppendorfs, one for galectin-3 assay
and the other for H-FABP assay; both were stored at 80 C
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collected for routine laboratory investigations: complete blood
count, erythrocyte sedimentation rate, C-reactive protein, liver
and kidney function test and serum electrolytes. Children who
have any abnormal findings suggestive of underlying illness
rather than VSD were excluded from the study.
Serum galectin-3 level. It was estimated using commercial
ELISA technique Kit from Glory Science co., Ltd, (Human
galectin-3 ELISA Kit). All frozen aliquots were placed on
the bench at room temperature until thawed to room temper-
ature. Also the kits were taken out from the refrigerator to
acquire the room temperature. 5 galectin standards were made
by pouring 120 ll of ready liquid standard (2400 pg/ml) in an
Eppendorf contained 120 ll of standard diluent and gentle
mixing was done (to be of 1200 pg/ml). Serial dilution was
done by adding 120 ll of this standard to the subsequent
Eppendorf containing 120 of standard diluent and so on until
5 serial standards were got (1200, 600, 300, 150, 75 pg/ml
respectively). The blank well was made by adding 50 ll of each
standard, streptavidin-HRP, chromogen A and chromogen B.
40 ll of the serial standards were added to the following wells
to the bank well and 40 ll of serum were added to the follow-
ing wells. Then 10 ll of galectin-3 antibody and 50 ll of
streptavidin were added to all wells except the blank one.
The plate was covered and shaken gently, and incubated for
60 min at 37 C. The diluent was prepared by diluting it 30
times (5 ml original washing + 145 ml deionized water).
Aspiration and washing four times using 400 ll volume from
the diluted washing solution were done. After each aspiration,
inversion and blotting against clean filter paper were done.
50 ll of chromogen A and 50 ll of chromogen B were added
to each well (except blank well) followed by gentle mixing
and incubation for 10 min at 37 C in dark. 50 ll of stop
solution were added. The plate was gently shaken to homoge-
nize the content. Reading was done by using ELISA Tecan
sunrise reader adjusted at 540 nm and 570 nm for background.
The first plate’s well reading was subtracted from all other
readings. The readings (OD) of the standards are plotted on
the X axis while the values were plotted on the Y axis. The
concentrations were obtained by interpolation.
Serum heart fatty acid binding protein (H-FABP) level. It was
estimated using commercial ELISA kit from Wuhan EIAab
Science Co., Ltd. All frozen aliquots were placed on the bench
at room temperature until thawed to room temperature. Also
the kits were taken out from the refrigerator and freezer to
acquire the room temperature. H-FABP standard was reconsti-
tuted by adding 1.0 ml of sample diluent and waiting 15 min
then gentle swirling done many times till it completely dissolved
(30 ng/ml). Serial 7 standard dilutions were made by pouring
200 ll of ready liquid standard (30 ng/ml) in an Eppendorf
contained 200 ll of sample diluent and gentle mixing was done
(to be of 15 ng/ml). Serial dilution was done by adding 200 ll of
this standard to the subsequent Eppendorf containing 200
of sample diluent and so on until 7 serial standards were got
(15, 7.5, 3.75, 1.88, 0.94, 0.47 and 0.0 (zero diluent only) ng/ml,
respectively). The blank well was prepared by adding 100 ll of
sample diluent. 100 ll of the serial standards were added to
the following wells to the bank well then 100 ll of serum were
added the followingwells. The detection reagentAwas prepared
by diluting it 100 times (2 ml original bottle + 198 ml assaydiluent). The plate was covered and shaken gently, and incu-
bated for 2 h at 37 C. The fluid contents were removed.
100 ll of the working detection reagent A solution were put in
each well. The plate was covered and shaken gently, and
incubated for 1 h at 37 C.Aspiration andwashing 3 times using
400 ll volume from the working wash buffer solution (1/50 dilu-
tion with deionized water) were done. After each aspiration,
inversion and blotting against clean filter paper were done.
100 ll of the working detection reagent B solution were put in
each well. The plate was covered and shaken gently, and incu-
bated for 1 h at 37 C. Aspiration and washing 5 times using
400 ll volume from the wash buffer solution were done. After
each aspiration, inversion and blotting against clean filter paper
were done. 90 ll of substrate solution were followed by gentle
mixing and incubation for 25 min at 37 C in dark. 50 ll of stop
solution were added. The plate was gently shaken to homoge-
nize the content. Reading was done by using ELISA Tecan
sunrise reader adjusted at 540 nm and 570 nm for background.
The first plate’s well reading was subtracted from all other
readings. The readings (OD) of the standards are plotted on
the X axis while the values were plotted on the Y axis. The
concentration was obtained by interpolation.
Statistical analysis
Statistical analysis was performed using the Statistical Package
for Social Sciences (version 17.0; SPSS Inc., Chicago, IL,
USA). Quantitative data were expressed as mean ± SD. Dif-
ferences between groups were analyzed with ANOVA test
and differences between groups were analyzed by post hoc
LSD teat. Non parametric data were compared by chi square
test. Correlations between groups were performed using
Spearman’s correlation coefficients. Receiver operating char-
acteristic curves (ROC) were used to identify the optimal
cut-off points of galectin-3 and H-FABP levels for prediction
of PH. P-value <0.05 was considered to be significant.Results
This study included 50 children with well-established diagnosis
of VSD (28 males and 22 females). In addition, 25 healthy chil-
dren served as a control group (12 male, 13 females). Their age
ranged between 6 and 48 months. Table 1 shows the general
characteristics, laboratory investigations, and echocardio-
graphic findings of the children included in the study. No sub-
stantial age and gender differences were found among children
involved in the study. As regards echocardiographic parame-
ters, patients with VSD had a more dilated, hypertrophied
right and left ventricle with lower EF%, a more dilated left
atrium, higher pulmonary pressure than healthy children.
Table 2 shows that serum level of galectin-3 and H-FABP
were significantly higher in patients with PH compared with
those without PH and control groups (P-value < 0.001).
ROC curve was plotted according to the data of the studied
groups. AUC was 0.765 when the level of plasma galectin-3
was more than 2.152 ng/ml. The sensitivity to predict PH in
patients with VSD was 76% and the specificity was 80%, while
AUC was 0.694 when the level of serum H-FABP was more
than 12.551 ng/ml. The sensitivity to predict PH in patients
with VSD was 60% and the specificity was 96% as demon-
strated in Fig. 1.
Table 1 Comparison of clinical, laboratory and echocardiographic data of the studied children.
Variables VSD with PH (n= 24) VSD without PH (n= 26) Control (n= 25) ANOVA/Chi-square test
F/X2 P-value
Age (months) 12.8 ± 6.357 18.4 ± 9.552 16.241 ± 11.369 2.293 0.108
Sex (n, %)
Male/Female 14 (58.3%)/10 (41.7%) 14 (53.8%)/12 (46.2%) 12 (48%)/13 (52%) 0.53 0.471
Laboratory data
HB (gm/dl) 11.276 ± 0.649 11.288 ± 0.719 11.344 ± 0.794 0.063 0.939
RBCs (106/mm3) 4.212 ± 0.564 4.331 ± 0.508 4.48 ± 0.621 1.405 0.252
WBCs (103/mm3) 7.884 ± 1.921 7.400 ± 1.749 7.58 ± 2.537 0.340 0.713
Platelet (103/mm3) 333.60 ± 90.046 359.12 ± 77.965 322.24 ± 110.154 1.047 0.367
ALT (U/L) 14.920 ± 2.343 14.200 ± 1.936 14.440 ± 1.781 0.812 0.448
AST (U/L) 11.200 ± 1.372 10.280 ± 1.429 11.080 ± 1.80 2.264 0.111
Urea (mg/dl) 19.76 ± 5.953 19.64 ± 7.75 18.84 ± 7.930 0.118 0.888
Creatinine (mg/dl) 0.472 ± 0.120 0.456 ± 0.071 0.488 ± 0.109 0.608 0.547
Echocardiographic data
Pulmonary Pressure (mmHg) 49.24 ± 9.152 20.52 ± 4.435 19.752 ± 4.835 166.850 0.000*
LVEDD (mm) 2.868 ± 0.738 2.52 ± 0.570 2.288 ± 0.5214 5.598 0.005*
LVESD (mm) 1.772 ± 0.436 1.56 ± 0.397 1.388 ± 0.406 5.398 0.007*
EF% 69.24 ± 4.648 71.36 ± 5.081 74.64 ± 5.655 6.990 0.002*
FS% 37.8 ± 3.674 39.36 ± 4.608 42.16 ± 4.997 6.130 0.003*
Sep (mm) 0.56 ± 0.104 0.496 ± 0.121 0.44 ± 0.0957 7.823 0.001*
PW (mm) 0.516 ± 0.102 0.476 ± 0.101 0.452 ± 0.122 2.184 0.120
RV (mm) 1.452 ± 0.547 1.096 ± 0.101 1.076 ± 0.136 10.200 0.000*
RA (mm) 1.896 ± 0.475 1.716 ± 0.371 1.592 ± 0.294 3.886 0.025*
AO (mm) 1.468 ± 0.265 1.468 ± 0.381 1.328 ± 0.271 1.695 0.191
HB: hemoglobin; RBCs: red blood cells; WBCs: white blood cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LVEED:
left ventricle end diastolic dimension; LVESD: left ventricle end systolic dimension; EF%: ejection fraction; FS%: fractional shortening; Sep:
septum; PW: posterior wall; RA: right atrium; RV: right ventricle; AO: Aorta.
* Significant.
Table 2 Serum level of galectin-3 and H-FABP in patients and control groups.
Variables VSD with PH (n= 24) VSD without PH (n= 26) Control (n= 25) ANOVA
F/X2 P-value
Galectin-3 (ng/ml) 2.889 ± 1.083 1.941 ± 0.707 1.038 ± 0.507 33.275 0.000*
H-FABP (ng/ml) 11.676 ± 8.283 4.493 ± 3.495 2.629 ± 1.140 20.834 0.000*
Variables VSD with PH vs VSD without PH VSD with PH vs control VSD without PH vs control
Post hoc: LSD test
Galectin-3 (ng/ml) 0.000* 0.000* 0.000*
H-FABP (ng/ml) 0.000* 0.000* 0.212
VSD: ventricular septal defect; PH: pulmonary hypertension; H-FABP: heart fatty acid binding protein.
* Significant.
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serum galectin-3 and H-FABP had a significant positive
correlation with pulmonary artery pressure (P-value < 0.05).
Additionally, there was significant positive correlation between
serum level of galectin-3 and H-FABP (P-value = 0.031).
However, galectin-3 and H-FABP have a positive correlation
with right ventricular dimensions and a negative correlation
with EF% but this correlation was statistically significant only
for H-FABP as demonstrated in Fig. 2.
Discussion
Pulmonary hypertension is a condition characterized by a pro-
gressive increase in pulmonary vascular resistance as a result ofnumerous pathological mechanisms. Left to right shunt is one
of the commonest causes of PH in children. An important
hemodynamic consequence of PH is its negative effect on right
ventricular function.13 In recent years, earlier recognition and
new treatment modalities have improved the outlook for
patients with PH.14
The elevated pulmonary artery pressure is irreversible and
leads to a reversal in the ventricular level shunt, desaturation,
and cyanosis. Eisenmenger syndrome represents the most
advanced form of PH associated with CHD. Early treatment
of medium and large sized VSD with large shunt volume should
be performed as early as possible to avoid development of PH.15
The prognostic assessment of pulmonary hypertension is
difficult but important, particularly in the context of optimal
Cut off point AUC Sensitivity Specificity PPV NPV
Galectin-3 (ng/ml) >2.152 0.765 76% 80% 79.2 76.9
H-FABP (ng/ml) >12.551 0.694 60% 96% 93.7 70.6
Figure 1 Sensitivity, specificity, and predictive values for PH diagnosis by galectin-3 and H-FABP level in children with VSD.
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of VSD is a noninvasive tool that accurately delineates the
morphology and associated defects. However, the drawback
of Doppler sonography is its operator-dependency. Therefore,
simple, non-invasive, and repeatedly available methods are still
needed.16
Biomarkers reflect aspects of the underlying disease process
can be very valuable additions to traditional risk stratification
models by providing an individualized risk profile to help
clinicians to direct resources to patients at high risk for adverse
outcomes.17
Recently, cardiac biomarkers reflecting myocardial remod-
eling and injury, such as galectin-3 and H-FABP gained
increasing interest. Galectin-3 represents a link between
inflammation and fibrosis18 while H-FABP reflects progressive
myocardial injury.19 Both biomarkers represent different
pathophysiological aspects that could provide complementary
information about the progression of pulmonary hypertension
and cardiac remolding. Such biomarkers can be of great value
for follow up during therapy.
The right ventricular (RV) adaptation to chronic pressure
and volume overload associated with PH is a complex that
includes compensatory hypertrophy, enlargement, changes in
contractile function, and fibrosis.20 An important predictor
of long-term outcome in patients with CHD is RV dysfunction
due to abnormal loading conditions.21
There is limited data about the utility of galectin-3 and
H-FABP as a predictor cardiac marker in children. For the
best of our knowledge, this is the first study to evaluate the role
of these markers for early detection of PH in children with left
to right shunt.
H-FABP could be a reliable biomarker in cardiac diseases
with myocardial damage such as pulmonary hypertension or
acute pulmonary embolism.22 H-FABP could serve as a new
monitoring tool to provide information that will guide the
optimal therapy and management of CHD patients.23 It is
superior to traditional biomarkers for the assessment of recur-
rent or persistent myocardial damage.24
Our results demonstrated that children with PH have signif-
icantly increased levels of H-FABP which is a cytosolic proteinthat has not been found outside the cell or in plasma under
normal conditions. H-FABP is released rapidly from the car-
diomyocyte in response to myocardial injury. Additionally,
its elevated level could reflect ongoing myocardial damage as
in patients with chronic heart failure.25 Recent evidence shows
that irreversible damage of the myocyte is not necessary;
rather, a leakage of small amounts of macromolecules can also
be caused by a reversible disturbance of cell metabolism or by
mechanical stretching mechanisms in which macromolecules
are released under moderate ischemic stress.26
There are contradictory data about the role of H-FABP for
evaluation of pulmonary hypertension. Lankeit et al.27
reported that H-FABP level was associated with increased risk
of death during long term follow-up in patients with chronic
thromboembolic pulmonary hypertension. On the other hand,
Schroetter et al.28 concluded that H-FABP fails to be a reliable
marker in pre-capillary pulmonary arterial hypertension or to
be a novel predictor of a long term outcome. This contradic-
tion could be explained by the different underlying pathophys-
iology in both studies.
Echocardiographic parameters of our studied patients
reviled that serum level of H-FABP had a significant positive
correlation with the right ventricular dimensions and negative
correlation with EF%. H-FABP may be elevated as a
consequence of right ventricular wall stress due to the highly
elevated right ventricular afterload.29 Our results showed that
serum H-FABP had lower sensitivity (60%) but higher speci-
ficity (96%) for prediction of PH in children with VSD at a
cut off point of more than 12.551 ng/ml.
Galectin-3 is a soluble ß-galactoside – binding lectin impli-
cated in pro-fibrotic pathways that is released by activated car-
diac macrophages in response to myocardial injury. It has been
shown to play an important role in pathological ventricular
remodeling and vascular fibrosis in animal models.30,31 Adult
studies showed that galectin-3 levels may be predictive of
raising pulmonary pressure, RV systolic function, diastolic
function, and morphology independent of left ventricular
systolic function.32
An advantage of using galectin-3 for assessing cardiovascu-
lar risk is that galectin-3 levels tend to be more stable over time
Figure 2 Correlations between serum galectin-3, H-FABP level and echocardiographic findings in children with VSD.
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uretic peptides or C-reactive protein.33
In spite of the growing evidence of the use of serum
galectin-3 in adult for diagnosis and risk stratification of
cardiac adverse events, there is limited data about the utility
of galectin-3 as a cardiac marker in children. Mohammedet al.34 demonstrated that serum galectin-3 level is a promising
cardiac biomarker which could reflect the progression of
ventricular remodeling in children with congenital acyanotic
heart diseases. This finding demonstrates the role of galectin-
3 as a marker of cardiac remodeling not only in adult but also
in children.
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children with PH in comparison to those without PH. Shah
et al.35 had demonstrated that elevated galectin-3 level associ-
ated with a higher RV systolic pressure. Galectin-3 is released
by RV myocardial macrophages as part of the right heart
adaptation to alterations in pulmonary arterial pressure and
volume and could be used as a biomarker for the RV response
to PH. Additionally; galectin-3 may reflect pulmonary arterial
extracellular matrix turnover.36,37 Galectin-3 has a role in the
pathological changes of the pulmonary arterial smooth muscle
cells with a consequent increase in the pulmonary vascular
resistance and development of PH.38
In adults, elevated galectin-3 was associated with echocar-
diographic parameters representative of impaired cardiac func-
tion and unfavorable remodeling.39 Our echocardiographic
study showed that galectin-3 has a positive correlation with
right ventricular dimensions and a negative correlation with
EF% but this correlation did not reach the statistical signifi-
cant value. As galectin-3 is a marker of ventricular remodeling
so long-term elevations in galectin-3 might precede the
development of cardiovascular disease.40
In comparison to H-FABP, serum galectin-3 had higher
sensitivity (76%) and lower specificity (80%) for prediction
of PH in children with VSD at a cut off point of more than
2.152 ng/ml.
Limitations of the study
One of the limitations of the current study is the small number
of patients included. As VSD is the commonest congenital
heart disease in children, it was available for us to collect suf-
ficient numbers of patients who have the same underlying
pathology and fulfill our inclusion and exclusion criteria
during the time frame of our study. Also, pulmonary pressure
was assessed using conventional echocardiography as we did
not have advanced echocardiography modes to evaluate
ventricular adaptation response to pressure overload. Further
large scale studies are required to apply our findings to all
cardiac defects with left to right shunt.
Our finding demonstrates that both galectin-3 and H-FABP
could be predictors for the development of PH among children
with VSD. Currently, there are several commercially available
assays that can measure circulating galectin-3 and H-FABP, if
validated, it will be a powerful tool in identifying risk and
simplifying the diagnosis of a condition that currently requires
costly investigations, subspecialist interpretations and early
management.
Conclusion
Galectin-3 and H-FABP are promising cardiac biomarkers for
PH diagnosis and risk stratification in children with VSD.
Serum levels of both markers are elevated in PH patients
and its level are correlated to PH severity and reflect the
progression of ventricular remodeling and allow early identifi-
cation of patients at high risk for development of PH. The
combination of these two biomarkers can serve as a monitor-
ing tool to guide the optimal management of patients with
VSD. Further researches confirming the structural correlations
observed in this study are needed.Conflict of interest
Authors declare no competing financial interests in relation to
this work.
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